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It would be very useful if it were possible to identify, within an
apparently normal population, those who will develop breast
cancer. Although this can be achieved by genetic testing for muta-
tions of BRCA1 and BRCA2, such susceptibility genes are
involved in the aetiology of only about 5% of breast cancer cases
(Lynch and Lynch, 1986). By contrast, events related to a woman’s
menstrual and reproductive history, which have been widely
recognized as determinants of breast cancer incidence, are not
impressive predictors of individual risks. Such poor predictive
performance could result from these epidemiological variables
being only manifestations of other underlying factors. Indeed the
size of the effects of the menstrual and reproductive variables and
the observation that breast cancer rates change over a woman’s life
have stimulated investigation of endogenous sex hormones as
potential causes underlying these observed effects (Key and Pike,
1988; Toniolo et al, 1995; Key et al, 1996). Methodological issues
related to hormone measurements, however, complicate the study
of their relationship with breast cancer. Furthermore, there is no
general consensus regarding which biological forms of these
hormones are actually associated with the observed changes in
incidence rates.
The role of steroids in the aetiology of breast cancer is uncer-
tain. Extensive analysis of the scientific literature shows a highly
significant increase in blood oestradiol levels in post-menopausal
women with breast cancer (Thomas et al, 1997). The position of
oestrogens and premenopausal women is uncertain (Key and Pike,
1988; Thomas et al, 1997). Androgens have been studied less
extensively than oestrogens and no meta-analysis has yet been
undertaken.
The first prospective study in this field was performed by
Bulbrook and Hayward who showed that levels of androsterone
(A) and aetiocholanolone (E) were abnormally low in women who
subsequently developed breast cancer (Bulbrook and Hayward,
1967; Bulbrook et al, 1971). Most of the cases were pre-
menopausal and the abnormality was present up to 11 years before
the clinical diagnosis of the disease, suggesting that high levels of
androgen metabolites might have a protective effect, at least in
younger women. However, other mainly retrospective case–
control studies have claimed that high androgen excretion is posi-
tively associated with breast cancer risk (e.g. Secreto and Zumoff,
1994). Such contrasting results could be reconciled if the effects of
androgens depended on menopausal status. This would occur if the
androgens acted as oestrogen inhibitors in premenopausal women
and as oestrogen enhancers (or even oestrogens) in the post-
menopausal (Secreto and Zumoff, 1994; Adams, 1998).
This paper is a further report on the prospective study of
Bulbrook and Hayward involving the long-term follow-up of a
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Summary Between 1961 and 1967 a cohort of over 5000 women volunteered for a prospective study to determine the relationship between
the urinary androgen metabolites, androsterone (A) and aetiocholanolone (E), and risk of breast cancer. During the first 10 years of the study
the concentration of urinary A and E was determined in 1887 of the urine specimens. In 1971 we reported that subnormal amounts of urinary
A and E were associated with a significantly increased risk of breast cancer. The cohort has been followed regularly during the 37 years since
inception of the study and, by May 1998, 248 women had been diagnosed with breast cancer. Urinary androgen metabolites had been
measured in 116 of these cases. Analysis of these data confirmed that women diagnosed in the first decade of the study were more likely to
have low levels of urinary androgen metabolites. In the following decades, however, those who developed breast cancer were more likely to
have manifested an increased A and E excretion. The reversal in the relationship between androgen metabolite excretion and risk suggests
that age, or probably more importantly, menopausal status at diagnosis is an important modifying factor. Dichotomizing at age 50 it was found
that in the younger age group (predominantly premenopausal) the rate ratios in the lowest tertile of A or E excretion were two- to threefold
greater than for those in the highest tertile (c2
1 = 3.57; P = 0.06: c2
1 = 4.70; P = 0.03 for A and E respectively). In contrast, in the older age
group comprising predominantly post-menopausal women, the rate ratios associated with the lowest tertile of A or E were half that of those in
the highest tertile (c2
1 = 4.10; P = 0.04; c2
1 = 8.72; P = 0.003 for A and E respectively). This suggests that there may be different endocrine
promotional factors for pre-and post-menopausal breast cancer. Hormonal risk factors may vary during the lifetime of an individual woman
and this may have profound consequences for prevention strategies. © 2000 Cancer Research Campaign
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urinary androgen metabolites are known. The cohort has been
followed at regular intervals for the last 38 years and presents a
unique opportunity to examine the long-term relationship between
the excretion of urinary androgen metabolites and breast cancer
risk.
SUBJECTS AND METHODS
Between 1961 and 1967 over 5000 women from the Channel
Island, Guernsey, volunteered to take part in a prospective study of
hormones and risk of breast cancer. Participation in the study
entailed collection of a 24-h urine specimen and self-completion
of a semi-structured questionnaire, which included information
about the woman’s date of birth, height and weight (both self-
reported), menstrual history (and number of days since last
menses, if premenopausal), reproductive history, medical history
(including family history of breast disease) and use of medication
in the past year.
The urine specimens were frozen, then sent to the laboratories in
London by air, where creatinine assays, to test for sample
completeness, were performed. A small number of specimens
were discarded on arrival in London due to thawing in transit, or
because glucose or protein was present in the specimen. The final
number of women held in the database for this Guernsey study
(GI) is 4921.
Follow-up
The cohort is being followed at 6-monthly intervals for diagnoses
of cancer, vital status and causes of death. This involves obtaining
pathology reports for cancer diagnoses from the island’s only
hospital, death certificates from the Director of Public Health for
Guernsey, and registrations for Guernsey women from the Wessex
Cancer Registry. Since 1996 all Guernsey cancers have been regis-
tered with the Wessex Cancer Registry, whereas previously only
women having radiotherapy or other treatment in Southampton
were so registered.
Changes of name through marriage or deeds poll were checked
at the island registry, the Greffe. By going through the GP records
from the six practices on the island it was estimated that follow-up
was 96% complete (Wang et al, 1992). Due to lack of resources we
have been unable to update this figure, but have no reason to
believe it has changed appreciably. For the purposes of these
analyses follow-up is to May 1998, with censoring at death or
diagnosis of any cancer. The median follow-up time of the
volunteers for whom there was no diagnosis of breast cancer is
33.4 years (interquartile range 30.9–35.5 years) (Table 1, ‘All’
columns).
Assays
From 1962 to 1964 the androgens were measured by the method of
Kellie and Wade (1957), using the fraction of urine containing the
17-oxosteroids, which had been stored at –20°C. From 1964 the
assay of androgen metabolites was performed using the method of
Thomas and Walton (1968). Comparison of these two methods
showed that the correlation of results for androsterone (A), or
aetiocholanolone (E), was highly significant (r > 0.9), and that the
slopes were statistically indistinguishable from unity (Thomas and
Bulbrook, 1966).
Because the earlier method was time-consuming, at the begin-
ning of the study assays were performed as breast cancer cases
were diagnosed (n = 19), together with appropriately selected
matched controls (Bulbrook and Hayward, 1967). The method of
Thomas and Walton (1968), together with an increase in funding
and staffing levels made it possible to do assays in a systematic
way between 1967 and 1971, starting from those urine samples
collected in the early years but not yet analysed. A total of 2162
measurements of A and E were performed.
Exclusions
Of the 4921 volunteers who participated in the study 409 were
excluded, either because they were prevalent cases or because
their underlying risk of breast cancer differed from that in the
general population. The exclusions were applied as follows: 23
women were prevalent cases of cancer at entry into the study and a
further three had breast cancer diagnosed within the first 6 months
of follow-up and therefore were classified as prevalent cases and
excluded; 364 women had had a hysterectomy and/or oophorec-
tomy before entry into the study and 19 were of unknown
menopausal status. Androgens were not measured on an additional
2625 specimens; 133 because their creatinine level was below
0.7 g per 24 h, four where creatinine was not measured, and 2490
due to lack of available funding for this purpose at that time.
Table 2 lists the main characteristics of the volunteers included
in the analyses and of those who were excluded either because of
ineligibility or lack of adequate androgen measurements. They are
generally very similar. It should be noted, however, that 80% of
the volunteers were premenopausal at entry to the study.
Statistical methods
Examination of the frequency distributions of A and E revealed
that they were skewed but that the distributions of their
log-transformed values were symmetrical. Regression analyses of
these log-transformed values therefore were used to evaluate their
relationship with age and menopausal status and showed that these
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Table 1 Follow-up time of the GI volunteers
All Included only
Cases Censored Total Cases Censored Total
n 248 4473 4921 116 1771 1887
Follow-up (years)
Median 23.4 33.4 17.0 32.9
Interquartile range (13.8–28.5) (30.9–35.5) (9.4–26.5) (31.2–35.6)variables needed to be accounted for when comparing androgen
levels with respect to breast cancer risks. To achieve this we classi-
fied women according to strata defined by age and menopause
categories and, within each stratum, assigned women into A and E
tertiles, adapting the method described by Zhang et al (1997) (see
Appendix). Stratum-specific rates for breast cancer incidence were
then estimated for these age- and menopause-adjusted tertiles of
androgen levels and for categories of the potential confounders for
which information had been collected: age at menarche (≤ 12, 13,
>13), parity (0, 1+), age at first birth (≤ 20, 21–25, > 25, nulli-
parous), self-reported height and weight (both in tertiles) and body
mass index (BMI = (wt (kg))/(ht(m))2; also in tertiles).
Cox regression models with current age as the time scale were
then fitted to the data in order to estimate age-adjusted rate ratios
(RRs) (Clayton and Mills, 1993). Because we excluded all cases
that occurred within the first 6 months of follow-up, the age at
entry into the study of all women included in the analyses was
shifted forward by 6 months. Assessment of the Cox proportion-
ality assumptions was performed by plotting separately the cumu-
lative incidence curves of the A and E tertiles (Aalen, 1978). These
revealed possible interactions between current age and the andro-
gens, effects that were further investigated by analysing separately
events that occurred before or after age 50 (see Appendix).
Potential confounders were also included in the model.
Assessment of linearity, heterogeneity and interaction were
performed by likelihood ratio tests.
RESULTS
The effect of age and menopausal status on androgen
levels
Both androgens generally decreased with age, reaching a plateau
after the menopause. Figure 1 shows the log-transformed values of
A plotted against the age at which the urine samples were collected
and Figure 2 shows the same results for E. Two regression lines are
shown for women who were pre- and post-menopausal at entry to
the study. There was no significant change in A and E levels with
age in post-menopausal women, although their overall level
differed from that of premenopausal women. Exclusion of extreme
values (i.e. lying outside the variable’s 95% range) did not change
the estimated intercepts or slopes. To examine the androgens’
effects on breast cancer risk, while controlling for variations due to
differences in age and menopausal status, we created age- and
menopause-specific tertiles of the two androgens, as described in
the Appendix.
Risk of breast cancer and androgen levels
The relationship between the age and menopause-adjusted tertiles
of A and E and breast cancer is shown in Table 3. It can be seen
that large values of the androgens appear to increase risk of breast
cancer, but these effects are moderate and not significant, without
a significant linear trend (c2
1 = 1.07, P = 0.30, and c2
1 = 3.07,
P = 0.08 respectively).
Risk of breast cancer, androgen levels and the effect of
confounding variables
The estimated RRs for the potential confounders revealed that
late age at menarche and early age at first birth had significant
protective effects (test for linear trend c2
1 = 4.21, P = 0.04, and
c2
1 = 15.80, P < 0.001 respectively), with parity indicating a
significant rate reduction of 40% (RR = 0.60, P = 0.02, in line with
most published results (Salber et al, 1969; Hsieh et al, 1990). The
estimated effects of the self-reported anthropometric variables
supported the evidence found in other studies of differential effects
in pre- and post-menopausal women, despite being self-reported
(Wang et al, 1997). BMI in particular showed significant protec-
tive effects for women who were premenopausal at entry (RR for
the second and third tertiles of BMI versus the first tertile were:
0.79 (95% confidence interval (CI) 0.51–1.21), 0.47 (95% CI
0.27–0.82), test for linear trend c2
1 = 7.37, P = 0.01) and harmful
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Table 2 Characteristics of the GI volunteers (by exclusion)
Included Excluded
Ineligible No androgensa
Subjects
(n and (cases)) 1887 (116) 409 (12) 2625 (120)
Premenopausal
(n and (%)) 1514 (80%) – – 2150 (82%)
Parous
(n and (%)) 1561 (83%) 317 (78%) 2122 (81%)
Age at entry
(Mean and (s.d.)) 42.1 (7.3) 46.5 (6.2) 41.9 (7.0)
Age at menarche
(Mean and (s.d.)) 13.3 (1.5) 13.3 (1.6) 13.4 (1.5)
Age at first birth
(Mean and (s.d.)) 26.0 (4.8) 24.7 (7.3) 25.4 (4.8)
Height (m)
(Mean and (s.d.)) 1.62 (0.06) 1.62 (0.06) 1.06 (0.07)
Weight (kg)
(Mean and (s.d.)) 62.5 (10.1) 63.7 (10.3) 62.7 (11.0)
BMI (kg m–2)
(Mean and (s.d.)) 23.8 (3.6) 24.3 (3.8) 24.0 (4.1)
aAmong those eligible.effects in those who were post-menopausal (RR for the second
and third tertiles of BMI versus the first tertile were: 2.61 (95%
CI 0.29–23.38), 6.35 (95% CI 0.81–49.63), test for linear trend
c2
1 = 5.78, P = 0.02). None of these factors, however, appeared
to confound the estimated RRs for the androgens shown in
Table 3.
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Figure 2 Observed values of log-transformed AETIO plotted against age and regression lines fitted on pre- and post-menopausal women (n = 1514 and
n = 373 respectively). Estimated intercepts: 8.11, P < 0.0001, for premenopausal women, and 7.41, P < 0.0001, for post-menopausal women. Estimated slopes:
–0.03, P < 0.0001, for premenopausal women, and –0.01, P = 0.32, for post-menopausal women
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Figure 1 Observed values of log-transformed ANDRO plotted against age and regression lines fitted on pre- and post-menopausal women (n = 1514 and
n = 373 respectively). Estimated intercepts: 8.50, P < 0.0001, for pre-menopausal women, and 7.45, P < 0.0001, for post-menopausal women. Estimated
slopes: –0.03, P < 0.0001, for pre-menopausal women, and –0.01, P = 0.27, for post-menopausal womenRisk of breast cancer, androgen levels and the effect of
current age
When the cumulative incidence rates for the separate tertiles of the
two androgens were plotted (on a log scale) to assess the propor-
tionality assumption underlying the Cox model, they converged
and crossed, from around the time of menopause (Figures 3 and 4).
To assess this formally, separate Cox regression models were
fitted after splitting breast cancer events and follow-up data
according to whether they occurred before or after (and including)
age 50, where 50 was chosen as the best estimate of the cohort
average age at menopause. Table 4 shows the results of these age-
band-specific estimates. In this analysis the RRs showed sig-
nificantly protective effects of high androgen levels in younger
women and significant harmful effects in older ones (linear tests
for trend when current age < 50, c2
1 = 3.57, P = 0.06, and
c2
1 = 4.70, P = 0.03 respectively; linear tests for trend when
current age ³50: c2
1 = 4.10, P = 0.04, and c2
1 = 8.72, P = 0.003
respectively). Note that 80 out of the 101 women were
premenopausal at entry but had a diagnosis of breast cancer after
age 50. They only moderately differed in terms of body size, but
not of androgen tertiles nor age at first birth, from the cases
who were already post-menopausal at entry. However, in order to
interpret these results, the RRs were re-estimated using the subset
of 382 women who were age 50 or older at entry. Among them,
19 had a diagnosis of breast cancer during their follow-up. The
results were consistent with those shown in Table 4 for age ≤ 50
years, especially considering the smaller numbers involved (RRs
for A: 0.96 (95% CI 0.31–2.91) and 1.25 (95% CI 0.42–3.72), test
for linear trend, P = 0.68; RRs for E: 1.37 (95% CI 0.42–4.49)
and 1.87 (95% CI 0.61–5.71), test for linear trend, P = 0.27). Tests
for interaction between the two age-bands (before and after
age 50) and the androgens were highly significant (c2
2 = 8.40,
P = 0.015, and c2
2 = 10.22, P = 0.006 respectively). Furthermore,
the results were not affected by the inclusion in the models of
reproductive or anthropometric variables, so no confounding due
to these factors could explain the results. When BMI was added
to the two models of Table 4, the estimated effects of the two
androgens were not substantially changed, indicating lack of
confounding. Indeed, there was no clear association in our data
between BMI and either of the two androgens, despite some
evidence that the effect of BMI changed with age.
DISCUSSION
The present results indicate a complex relationship between the
level of urinary androgen metabolite excretion and risk of breast
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Table 3 Distribution of breast cancer cases in the volunteers included in the analyses, associated rates and age-adjusted RRs by age and menopause specific
tertiles of androgens
Factor Category n Cases Rate (95% CI) RR (95% CI)
(per 1000)
Overall 1887 116 2.07a (1.73–2.48)
ANDRO 1st tertile 635 35 1.88 (1.35–2.61) 1
2nd tertile 644 38 1.98 (1.44–2.72) 1.05 (0.66–1.66)
3rd tertile 608 43 2.37 (1.76–3.19) 1.26 (0.81–1.97)
Trend test c2
1 = 1.07 P = 0.30
AETIO 1st tertile 635 33 1.77 (1.26–2.49) 1
2nd tertile 645 36 1.85 (1.34–2.57) 1.04 (0.65–1.68)
3rd tertile 607 47 2.61 (1.96–3.47) 1.47 (0.94–2.30)
Trend test c2
1 = 3.07 P = 0.08
aThe overall crude rate may be moderately over-estimated due to the slight over-representation of early cases. However, the rate ratios should not be affected.
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Figure 3 Cumulative baseline rates of the three tertiles of ANDRO plotted
on a log-scale. If the cumulative rates differed by a constant amount over the
entire age period, the three curves should be parallel. Coding of ANDRO:
1 = 1st tertile, 2 = 2nd tertile, 3 = 3rd tertile
Figure 4 Cumulative baseline rates of the three tertiles of AETIO plotted on
a log-scale. If the cumulative rates differed by a constant amount over the
entire age period, the three curves should be parallel. Coding of AETIO:
1 = 1st tertile, 2 = 2nd tertile, 3 = 3rd tertilecancer. In the first decade of follow-up, low levels of A and E are
associated with an increase in the risk of disease while in the third
decade this tendency is reversed. Why the predictive value of A
and E should undergo such a reversal can only be speculated upon.
It is unlikely to be methodological since all of the urinary assays
were performed in the first decade of the follow-up period.
Implicit in these suggestions is the assumption that the level of
A and E excretion (and androgen secretion) is characteristic of a
woman; thus a high secretor will remain so, or relatively so,
permanently. For many obvious reasons there are no experimental
data on the changes in androgen production in a cohort of women
for a period of time as long as 35 years. However, we do have indi-
rect evidence that supports this assumption. A total of 294 women
from the present cohort gave blood specimens for another phase
of the research study about 15 years later. Concentrations of
dehydroepiandrosterone (D) and dehydroepiandrosterone sulphate
(DS) were measured on these samples. We have found a highly
significant association between these blood androgens and the
levels of urinary A and E in these women (Cramer’s V (test of
association) = 0.269, 0.278, 0.211, 0.236, all P < 0.001, for A with
D, A with DS, E with D, E with DS respectively).
Over 80% of the cohort were premenopausal at entry into the
trial which implies that women who developed breast cancer early
in the follow-up period would have been predominantly
premenopausal. As the follow-up time increased, the cohort would
have passed through the menopausal years with the effect that later
cases would have been post-menopausal at diagnosis. Thus a
possible explanation could be that the relationship between
androgen levels and breast cancer risk varies according to
menopausal status.
The notion that there are two types of breast cancer, defined by
menopausal status, has been in the scientific literature for over 30
years and recently reviewed by Adams (1998). The hypothesis was
advanced that premenopausal breast cancer was the result of an
endocrine dysfunction involving ovarian oestrogens, whereas the
post-menopausal type involved adrenal oestrogens (De Waard
et al, 1960, 1964). A two-disease mathematical model has been
described by Manton and Stallard (1980) based on American
breast cancer mortality rates which successfully predicted the age
frequency of breast cancer deaths over an age range of 25–94
years.
In a review of the evidence for the existence of two types of
human breast cancer, Adams (1983) compared the high breast
cancer rates of Western Europe with the low rates in countries such
as Japan. He points out that, post-menopausally, the European age-
specific rates form approximate straight lines after subtracting the
Japanese rates. These rates are termed ‘Western environmental
type’ by De Waard (1969). This could imply that postmenopausal
breast cancer might be the result of prolonged hormonal and
environmental factors. This would be consistent with the report of
Hayward et al (1978) that the lower incidence of breast cancer in
post-menopausal Japanese women, living in Japan, compared to
Western women, and the rise in incidence in migratory Japanese
women is reflected in the levels of serum DS. It is possible, there-
fore, that low urinary androgen metabolites predict a high risk of
early onset breast cancer, and that high levels are associated with
an increased risk in the late, or post-menopausal, disease.
There are a large number of reports associating high androgen
status in post-menopausal women with breast cancer (Grattarola et
al, 1974; McFadyen et al, 1976; Adami et al, 1979; Secreto et al,
1983, 1991; Hill et al, 1985; Secreto and Zumoff, 1994; Dorgan
et al, 1996; Thomas et al, 1997; Zeleniuch-Jacquotte et al, 1997).
The post-menopausal type of disease could be influenced by
oestrogens from the metabolism of adrenal androgens. This could
come about by two pathways. The first is the aromatization of
dehydroepiandrosterone by breast and adipose tissue and the
conversion of oestrone to oestradiol. Thomas et al (1997) have
reported a significant correlation between the serum levels of
oestradiol and testosterone. The second mechanism derives from
5-androstene-3b,17b-diol, an important metabolite of dehydro-
epiandrosterone. The former steroid can compete with oestradiol
for oestrogen receptors. Earlier studies demonstrated unique
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Table 4 Age-band specific rates and rate ratios (RRs) for age and menopause specific tertiles of androgens
Age-band < 50 Age-band ³ 50
Cases Rate (95% CI) RR (95% CI) Cases Rate (95% CI) RR (95% CI)
Overall 21 1.40a (0.91–2.15) 95 2.31a (1.89,2.83)
ANDRO
(tertiles)
1st 12 2.43 (1.38–4.27) 1 23 1.68 (1.12–2.53) 1
2nd 4 0.78 (0.29–2.08) 0.32 (0.10–0.99) 34 2.41 (1.72–3.38) 1.43 (0.84–2.43)
3rd 5 1.02 (0.43–2.45) 0.42 (0.15–1.19) 38 2.86 (2.08–3.94) 1.70 (1.02–2.86)
Trend test c2
1 = 3.57 c2
1 = 4.10
(P = 0.06) (P = 0.04)
Test for c2
2 = 8.40
interaction (P = 0.015)
AETIO
(tertiles)
1st 11 2.22 (1.23–4.01) 1 22 1.61 (1.06–2.45) 1
2nd 7 1.36 (0.65–2.85) 0.61 (0.24–1.57) 29 2.03 (1.41–2.93) 1.26 (0.73–2.20)
3rd 3 0.62 (0.20–1.91) 0.28 (0.08–0.99) 44 3.35 (2.49–4.50) 2.08 (1.24–3.46)
Trend test c2
1 = 4.70 c2
1 = 8.72
(P = 0.03) (P = 0.003)
Test for c2
2 = 10.22
interaction (P = 0.006)
aThe overall crude rate may be moderately over-estimated due to the slight over-representation of early cases. However, the rate ratios should not be affected.oestrogenic effects in the rat (Huggins et al, 1954), and more
recently that, at concentrations found in the blood of Western
women, it both increased uterine growth and DNA synthesis in
this species (Seymour-Munn and Adams, 1983). Because of the
androgenic origins of this oestrogen-like compound it has been
dubbed ‘hermaphrodiol’ by Adams (1983). In normal breast tissue
there is a highly significant correlation between the concentrations
of D (or its sulphate ester) and 5-androstene-3b,17b-diol diol
(Bonney et al, 1984). Thus high levels of D imply correspondingly
increased concentrations of 5-androstene-3b,17b-diol. It has
already been shown that there is a highly significant correlation
between the amount of blood-borne D (or its sulphate ester) and
the concentration of urinary A or E excreted (Wang et al, 1979).
For this reason, the high urinary excretion of A or E could imply
increased steroid substrates for oestradiol and 5-androstene-
3b,17b-diol.
The initial results of the study (Bulbrook and Hayward, 1967;
Bulbrook et al, 1971) came mainly from premenopausal women in
whom a low discriminant function (i.e. low androgen relative to
hydroxycorticoid excretion) was associated with increased breast
cancer risk. The discriminant function reflects the relative secre-
tions of D and cortisol. Reed (1995) has suggested that these
steroids have a profound effect on T-helper cells which can express
either a Th1 or a Th2 phenotype. Th1 and Th2 cells are character-
ized by the secretion of a unique battery of cytokines. Th1 cells
secrete interferon g (IFN-g), interleukin-2 (IL-2) and tumour
necrosis factor b (TNF-b) whilst Th2 cells produce IL-4, IL-5,
IL-6 and IL-10. Th1 and Th2 cells tend to be mutually exclusive in
that IFN-g (Th1) inhibits the secretion of Th2 cytokines whilst
IL-10 (Th2) inhibits the Th1 cytokine response. The paradigm
suggested by Reed is that a low androgen to cortisol ratio would
favour Th2 cells and the production of IL-6, a cytokine which
up-regulates oestrogen synthesis in breast tissue.
The present results suggest that the endocrine components of the
aetiology of early and late onset breast cancer may be different. If
premenopausal breast cancer is the result of the effects of
cytokines against the background of full ovarian activity and post-
menopausal disease is the long-term effect of slight hyperoestroge-
nization then this could have a profound impact on prevention. It
might explain why the incidence of genetically driven disease,
predominantly premenopausal, is not significantly reduced by the
administration of tamoxifen (Powles et al, 1998; Veronesi et al,
1998). In contrast to these negative findings, the NSABP P1 trial
which included substantial numbers of post-menopausal women
(one of the entry criteria being aged > 60), showed a significant
reduction in incidence of breast cancer in all age groups given
tamoxifen (Fisher et al, 1998). Our findings suggest that endocrine
factors which are protective in premenopausal women may reverse
their role after the menopause leading to the emergence of an
increased risk of developing breast cancer.
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APPENDIX
Tertile analysis
The individual androgen levels, measured at entry to the study,
were standardized as follows. We classified the women according
to several strata; firstly by menopausal status (pre and post) and
then, within each menopausal group, into several categories of age
at entry (from age 30 to age 55 in 2-yearly intervals plus an addi-
tional category for age 56–60). Within each stratum we ranked
the women according to their A values and classified them as
belonging to either the first, second or third tertile. The same
method was used for E. Hence, the observed values of both andro-
gens were categorized into tertiles after accounting for the effect of
age and menopausal status.
Age-specific Cox regressions
To fit separate Cox regression models over the two separate age
intervals, before 50 and after and including 50, we manipulated the
data as follows:
• If a woman was younger than 50 years at entry to the study,
and was still followed up after her 50th birthday, her follow-up
information was split into two parts. The first would hold the
length of the follow-up to age 50, with an indicator that she
was disease-free at that age; the second part would indicate the
length of the remaining follow-up time after age 50 and
whether or not she was still disease-free at the end. Thus, if
she had cancer diagnosed during the latter period, her event
would appear in the analyses for age 50 or over
• If a woman was younger than 50 at entry, but her follow-up
ended before her 50th birthday, no data expansion would be
made. If she had been diagnosed with breast cancer at the end
of her follow-up, her event would contribute to the number of
pre-age 50 events.
If a woman was older than 50 at entry no data expansion was
made. If she had been diagnosed with breast cancer at the end
of her follow-up, her event would contribute to the number of
post-age 50 events.
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